SPARTAN: A Study of Apalutamide in Men with M0 Castration-Resistant Prostate Cancer (M0 CRPC) - Alan Bryce
March 21, 2018
Alan Bryce provides an overview of results from SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer - and the subsequent FDA approval of apalutamide for treatment of men with M0 castration resistant prostate cancer ( M0 CRPC). The presentation includes a review of the data on the primary and secondary endpoints and the results on overall survival, hazard ratio, toxicities. Alan Bryce and E. David Crawford discuss the trial impacts in clinical practice.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
First Presentation - SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer
Apalutamide Delayed CRPC Metastasis by More Than 2 Years - SPARTAN
Alan Bryce, MD. is the Medical Director of the Genomic Oncology Clinic at Mayo Clinic Arizona where he utilizes whole genome sequencing of tumors to identify key driver mutations. His clinical practice centers on genitourinary malignancies (prostate, kidney, bladder, and testicular cancers) and melanoma. Dr. Bryce participates in community outreach to underserved populations and has in interest in health disparities research. He conducts Phase I clinical trials of new cancer drugs.
E. David Crawford, MD.